Adlai Nortye
Business Services · China · 51-200 Employees
View Company Info for Free
Overview
Headquarters
no.452 6th St 21 Fl Bldg No.2, Shaoxing,...Phone Number
(848) 230-7430Website
www.adlainortye.comRevenue
$5 MillionStock Symbol
ANLIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Adlai Nortye
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2004, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates includeRead more
Adlai Nortye Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Adlai Nortye your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Adlai Nortye launches new products
Adlai Nortye, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Adlai Nortye has new funding data
Check if Adlai Nortye has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Adlai Nortye recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Adlai Nortye
Click to see if Adlai Nortye had a recent Job posting/layoffs
Check out if Adlai Nortye is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Adlai Nortye as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Adlai Nortye is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Adlai Nortye is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Adlai Nortye.
Adlai Nortye financials insights
Gather financial insights about Adlai Nortye, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series B
$53M
2020
Series C
$100M
2021
Series D
$100M
Adlai Nortye Tech Stack
A closer look at the technologies used by Adlai Nortye
See more technologies
Most Recent Scoops
Person-Based
Project
Adlai Nortye has reported that its oral PI3K inhibitor AN9025 demonstrates over 34-fold greater biochemical potency compared to the market leader, translating to approximately 10-fold greater cellular potency and an additional approximately 25- to 27-fold improvement in vivo, with a projected human half-life of approximately 40 hours.
Medical Research, Pharmaceuticals
Project
Adlai Nortye has reported preclinical therapeutic index (TI) estimates for AN9025 benchmarked against divarasib, showing a projected human TI of 6.9 for AN9025 versus 5.3 for divarasib, with comparable or slightly better TI results also observed in mouse and rat models, despite AN9025 being approximately 250- to 274-fold more potent than divarasib.
Project
Adlai Nortye has demonstrated preclinically that once-daily and once-weekly dosing schedules for AN9025 produce equivalent efficacy when the total weekly dose is held constant, a finding reproduced across three xenograft models including cholangiocarcinoma, melanoma, and lung cancer.
Project
Medical Research, Pharmaceuticals, Clinical Operations
Adlai Nortye News & Media
Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia
First-in-class pan-RAS(ON) ADC is cleared for clinical developmentAdlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
The first patient has been dosed in the intermittent weekly dosing (QW) arm of the ongoing Phase 1 clinical trial of AN9025, a pan-RAS(ON) inhibitor.Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
SINGAPORE and NORTH BRUNSWICK, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the expansion of its Scientific Advisory Board (SAB) with the appointments of two leading medical oncologists, Dr. David S. Hong and Dr. Piro Lito.Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
SINGAPORE and NORTH BRUNSWICK, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $150.0 million, before deducting placement agent fees and other private plac
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Adlai Nortye
Sign Up For FreeTo access detailed company insights
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2004, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinom... Read More
